Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. August 2023 08:30 ET | Quelle: Imunon, Inc.

IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023

LAWRENCEVILLE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
27. Juni 2023 12:00 ET | Quelle: Imunon, Inc.

IMUNON Unveils New Manufacturing Capabilities at Huntsville’s HudsonAlpha Biotech Campus

Production of cGMP Clinical Materials Supports R&D Efficiencies and Lowers Costs for Infectious Disease and Cancer Vaccines, and Non-viral DNA-based Immuno-Oncology Therapies HUNTSVILLE, Ala.,...
01. März 2023 08:45 ET | Quelle: Imunon, Inc.

IMUNON CEO Issues Letter to Shareholders

Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
12. Januar 2023 08:30 ET | Quelle: Imunon, Inc.

IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses

Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025The sale of an additional $1.8 million of unused New Jersey NOLs expected in 2023 LAWRENCEVILLE, NJ,...
03. Oktober 2022 17:00 ET | Quelle: Imunon, Inc.

Imunon Appoints James E. Dentzer to its Board of Directors

CEO of Curis brings extensive biopharmaceutical financial experience to the Board LAWRENCEVILLE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (Nasdaq: IMNN), a clinical-stage drug...